Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells $139,809.20 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total transaction of $139,809.20. Following the completion of the transaction, the insider now owns 247,173 shares in the company, valued at approximately $8,952,606.06. The trade was a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total value of $143,228.80.

Apogee Therapeutics Stock Down 7.6 %

APGE opened at $32.32 on Monday. The firm has a market cap of $1.46 billion, a PE ratio of -13.36 and a beta of 1.72. The business has a fifty day simple moving average of $37.21 and a 200-day simple moving average of $45.40. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). On average, equities research analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Analysts Set New Price Targets

APGE has been the topic of several recent research reports. Wedbush reissued an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Citigroup began coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 target price on the stock. Finally, Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics has an average rating of “Buy” and an average target price of $92.17.

Institutional Trading of Apogee Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of APGE. GF Fund Management CO. LTD. purchased a new stake in Apogee Therapeutics in the 4th quarter worth about $43,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Apogee Therapeutics in the 3rd quarter valued at about $71,000. Wexford Capital LP purchased a new stake in shares of Apogee Therapeutics in the third quarter worth approximately $230,000. Optimize Financial Inc acquired a new stake in shares of Apogee Therapeutics during the fourth quarter worth approximately $203,000. Finally, Aigen Investment Management LP purchased a new position in Apogee Therapeutics during the fourth quarter valued at approximately $216,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.